Results of Part A of KALAHARI, a Phase 2 Trial of THR-149, a plasma kallikrein (pKal) inhibitor, for the treatment of diabetic macular oedema (DMO)
Author: Timothy Jackson
Co-authors: Joel A Pearlman, David J Warrow, Victor H Gonzalez, Rahul N Khurana, David S Boyer